IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients
Recent advances in the treatment of hematologic malignancies have improved the overall survival rate, but the number of patients at risk of developing an invasive fungal infection (IFI) has increased. Invasive infections caused by non-<i>Candida albicans</i> species, non-<i>Aspergi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Journal of Fungi |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2309-608X/9/6/628 |
| _version_ | 1797593965162135552 |
|---|---|
| author | Carlos Vallejo Isidro Jarque Jesus Fortun Araceli Casado Javier Peman |
| author_facet | Carlos Vallejo Isidro Jarque Jesus Fortun Araceli Casado Javier Peman |
| author_sort | Carlos Vallejo |
| collection | DOAJ |
| description | Recent advances in the treatment of hematologic malignancies have improved the overall survival rate, but the number of patients at risk of developing an invasive fungal infection (IFI) has increased. Invasive infections caused by non-<i>Candida albicans</i> species, non-<i>Aspergillus</i> molds, and azole-resistant <i>Aspergillus fumigatus</i> have been increasingly reported in recent years. We developed a cross-sectional multicenter survey which involved a total of 55 hematologists and infectious disease specialists from a total of 31 Spanish hospitals, to determine the most frequent strategies used for the management of IFIs. Data collection was undertaken through an online survey which took place in 2022. Regarding key strategies, experts usually prefer early treatment for persistent febrile neutropenia, switching to another broad-spectrum antifungal family if azole-resistant <i>Aspergillus</i> is suspected, broad-spectrum azoles and echinocandins as prophylactic treatment in patients receiving midostaurin or venetoclax, and liposomal amphotericin B for breakthrough IFIs after prophylaxis with echinocandins in patients receiving new targeted therapies. For antifungals failing to reach adequate levels during the first days and suspected invasive aspergillosis, the most appropriate strategy would be to associate an antifungal from another family. |
| first_indexed | 2024-03-11T02:16:01Z |
| format | Article |
| id | doaj.art-00c19741fe52413ab556c1992760c340 |
| institution | Directory Open Access Journal |
| issn | 2309-608X |
| language | English |
| last_indexed | 2024-03-11T02:16:01Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Fungi |
| spelling | doaj.art-00c19741fe52413ab556c1992760c3402023-11-18T11:08:37ZengMDPI AGJournal of Fungi2309-608X2023-05-019662810.3390/jof9060628IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic PatientsCarlos Vallejo0Isidro Jarque1Jesus Fortun2Araceli Casado3Javier Peman4Hematology Department, Clinic University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, SpainHematology Department, Hospital La Fe, 46026 Valencia, SpainInfectious Diseases Department, Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, 28034 Madrid, SpainPharmacoeconomics and Outcomes Research Iberia (PORIB), 28224 Madrid, SpainMicrobiology Department, Hospital La Fe de Valencia, 46026 Valencia, SpainRecent advances in the treatment of hematologic malignancies have improved the overall survival rate, but the number of patients at risk of developing an invasive fungal infection (IFI) has increased. Invasive infections caused by non-<i>Candida albicans</i> species, non-<i>Aspergillus</i> molds, and azole-resistant <i>Aspergillus fumigatus</i> have been increasingly reported in recent years. We developed a cross-sectional multicenter survey which involved a total of 55 hematologists and infectious disease specialists from a total of 31 Spanish hospitals, to determine the most frequent strategies used for the management of IFIs. Data collection was undertaken through an online survey which took place in 2022. Regarding key strategies, experts usually prefer early treatment for persistent febrile neutropenia, switching to another broad-spectrum antifungal family if azole-resistant <i>Aspergillus</i> is suspected, broad-spectrum azoles and echinocandins as prophylactic treatment in patients receiving midostaurin or venetoclax, and liposomal amphotericin B for breakthrough IFIs after prophylaxis with echinocandins in patients receiving new targeted therapies. For antifungals failing to reach adequate levels during the first days and suspected invasive aspergillosis, the most appropriate strategy would be to associate an antifungal from another family.https://www.mdpi.com/2309-608X/9/6/628invasive fungal infection<i>Aspergillus fumigatus</i>antifungal therapyazole-resistant <i>Aspergillus</i>emerging moldsnew targeted therapies |
| spellingShingle | Carlos Vallejo Isidro Jarque Jesus Fortun Araceli Casado Javier Peman IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients Journal of Fungi invasive fungal infection <i>Aspergillus fumigatus</i> antifungal therapy azole-resistant <i>Aspergillus</i> emerging molds new targeted therapies |
| title | IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients |
| title_full | IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients |
| title_fullStr | IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients |
| title_full_unstemmed | IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients |
| title_short | IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients |
| title_sort | ifistrategy spanish national survey of invasive fungal infection in hemato oncologic patients |
| topic | invasive fungal infection <i>Aspergillus fumigatus</i> antifungal therapy azole-resistant <i>Aspergillus</i> emerging molds new targeted therapies |
| url | https://www.mdpi.com/2309-608X/9/6/628 |
| work_keys_str_mv | AT carlosvallejo ifistrategyspanishnationalsurveyofinvasivefungalinfectioninhematooncologicpatients AT isidrojarque ifistrategyspanishnationalsurveyofinvasivefungalinfectioninhematooncologicpatients AT jesusfortun ifistrategyspanishnationalsurveyofinvasivefungalinfectioninhematooncologicpatients AT aracelicasado ifistrategyspanishnationalsurveyofinvasivefungalinfectioninhematooncologicpatients AT javierpeman ifistrategyspanishnationalsurveyofinvasivefungalinfectioninhematooncologicpatients |